November 22, 2021

Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

Today, Biogen and Eisai announced that the Journal of the American Medical Association (JAMA) Neurology published a peer-reviewed paper about findings around amyloid-related imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa).

April 19, 2021

18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy

Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment TOKYO , April 19, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts , CEO: Michel Vounatsos , "Biogen") today

April 19, 2021

Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

Initial findings from the DEVOTE study suggest no new safety concerns and support continued development of a higher dose of SPINRAZA ® (nusinersen) Additional research reinforces the potential of biomarkers and highlights new digital tools that may help guide future treatment approaches and

April 16, 2021

New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

New findings from MS PATHS show that treatment with TYSABRI ®  (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus ® (ocrelizumab) Real-world data from VUMERITY ® (diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability

April 15, 2021

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs More than 500,000 individuals worldwide living with multiple sclerosis (MS) have been treated with TECFIDERA, which has a well-established safety and

April 14, 2021

Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021

CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual

April 12, 2021

Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint

Statistically significant reduction in tremor score compared to placebo at Day 29 in adults with essential tremor SAGE-324 demonstrated a 36% reduction in upper limb tremor amplitude from baseline at Day 29 in the total studied population; in a more severe population (baseline TETRAS Upper Limb

April 9, 2021

Biogen Announces Two New Nominees for Election to Board of Directors

Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscience Company thanks Director Robert W. Pangia as he retires from the Board CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.

April 8, 2021

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab) Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost savings and

April 7, 2021

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis

TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients' individual preferences and needs The subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians

March 4, 2021

Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina

The innovative and scalable gene therapy manufacturing facility will support Biogen’s plan to advance its gene therapy portfolio The new facility is expected to employ approximately 90 people and to be operational by 2023 CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.